

Financial Tear Sheet

Corporate Profile

INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of patients' lives.

Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, SUBSYS[®], a sublingual Fentanyl spray for breakthrough cancer pain launched in March of 2012, and SYNDROS[®], the first and only FDA-approved liquid dronabinol for loss of appetite in AIDS patients and nausea and vomiting caused by anti-cancer medicine (chemotherapy). Please see full prescribing information for SUBSYS[®] and SYNDROS[®] including the boxed warning.

Our product pipeline is aimed at addressing conditions with unmet medical needs, such as refractory pediatric epilepsy (including childhood absence epilepsy and infantile spasms), the genetic disorder Prader-Willi syndrome, anorexia-associated weight loss in cancer patients, agitation in Alzheimer's disease, migraine, anaphylaxis (severe allergic reaction), acute pain, opioid dependence and reversal of opioid-induced respiratory depression.

SEC FILINGS

FILING DATE	FORM
05/14/18	4
05/10/18	10-Q
05/10/18	4
05/10/18	4

INSYS Therapeutics, Inc.

Attn: Secretary of the Board of Directors
1333 South Spectrum Blvd, Suite 100
Chandler, AZ 85286
Phone: (602) 910-2617
Fax: (602) 910-2627

Stock Information

INSY (COMMON STOCK)	
Exchange	NASDAQ GS (US Dollar)
Price	\$6.86
Change (%)	▼ 0.21 (2.97%)
Volume	179,087
52 Week Low	\$4.10
Market Cap	\$506,329,081
Rolling EPS	-3.23
PE Ratio	0
Shares Outstanding	73,808,904
Data as of 05/25/18 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

DATE	TITLE
05/22/18	INSYS Therapeutics Confirms Outcome of FDA Advisory Committee Meeting on Buprenorphine Sublingual Spray
05/15/18	INSYS Therapeutics Responds to Unsealing of Previously Filed Qui Tam Complaints and Recaps Transformation Efforts
05/08/18	INSYS Therapeutics Announces Exclusive License Partnership with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East

Upcoming Events

There are currently no events scheduled.

Ownership Profile

SHAREHOLDERS				
	Holders	Value (\$MM)	% O/S	Shares
Institution	174	473.52	87.6	64,646,026
Mutual Fund	152	79.01	14.2	10,507,197
Insider *	5	1.18	0.2	130,465

*Insider values reflect direct beneficial ownership.

TOP HOLDERS				
	Shares Held	% O/S	Share Change	Filing Date
John N. Kapoor Trust	42,447,810	57.5	17,500	02/27/18
Kapoor Children's 1992 Trust	4,557,950	6.2	0	03/15/17
OrbiMed Advisors, LLC	3,511,544	4.8	-1,895,300	03/31/18
The Vanguard Group, Inc.	2,390,002	3.2	-147,084	03/31/18
BlackRock Institutional Trust Company, N.A.	2,326,890	3.2	-66,777	03/31/18
Horizons ETFs Management (Canada) Inc.	1,928,978	2.6	516,058	03/31/18
APG Asset Management	1,114,542	1.5	279,298	03/31/17
Norges Bank Investment Management (NBIM)	985,712	1.3	0	12/31/17
ETF Managers Group, LLC	649,898	0.9	367,630	03/31/18
State Street Global Advisors (US)	448,681	0.6	-6,540	03/31/18